Physician profile
Valentin Bragin
NPI 1134114135
$2,945.59
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,646 · 2020: $193 · 2021: $670 · 2022: $437.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $437.67 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $383.97 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $380.00 | 2020-2022 | |
| Abbvie INC. | $377.00 | 2019-2022 | |
| Allergan, INC. | $367.97 | 2019 | |
| Lundbeck LLC | $282.19 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $277.55 | 2019 | |
| Janssen Pharmaceuticals, INC | $203.57 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $82.06 | 2021-2022 | |
| Vivus LLC | $57.99 | 2021-2022 | |
| Eisai INC. | $45.57 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $32.55 | 2020 | |
| Alkermes, INC. | $17.50 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Valentin Bragin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.